Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

ReportsWorldwide has announced the addition of a new report title Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products to its growing collection of premium market research reports.

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20-45% in the general population, and up to 90% in obese patients. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence, mainly due to the rising prevalence of obesity.

FLD is increasingly recognized as a major global health problem. However, despite this the FLD market is still in its infancy, with no FDA-approved drugs for this indication, and only a limited number of generic drugs approved in non-US markets in recent years.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/frontier-pharma-fatty-liver-disease---high-degree-of-first-in-class-innovation-dominated-by-nuclear-receptor-targeting-nash-products

FLD has an active pipeline and first-in-class products account for a considerable proportion, which is very promising considering the level of unmet need and lack of approved treatment options. First-in-class innovation is concentrated heavily at the early drug development stages, and prominent first-in-class molecular targets include nuclear receptors, immune mediators, and molecules involved in lipid synthesis. Additionally, the first-in-class targets identified show considerable diversity, reflecting the multifaceted aspects of FLD pathophysiology.

Key topics covered in this report :

FLD comprises a diverse patient population with significant unmet needs

- What is the pathophysiology of FLD?
- What are the common co-morbidities and complications?
- What are the most significant unmet needs within the market?

The FLD pipeline is relatively large and has a high degree of first-in-class innovation

- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The FLD deal landscape shows rising deal volumes and considerable investment opportunities

- Do FLD products attract high deal values?
- Which molecule types and molecular targets dominate the deals landscape?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=35934

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.